Notable Labs

Notable Labs CROIC

The Cash Return on Invested Capital (CROIC) of Notable Labs (NTBLQ) as of Nov 17, 2026 is -89.17 %. In the previous year, Cash Return on Invested Capital (CROIC) was -144.32 % — a change of -38.21% (higher).

CROIC

-89.17 %

YoY

-38.21%

Last updated:

Cash Return on Invested Capital (CROIC) of Notable Labs is 2023 -89.17 % . Cash Return on Invested Capital (CROIC) of Notable Labs was 2022 -144.32 % . It decreases by -38.21% higher compared to the previous year.

The Notable Labs CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2016
-32.78 USD
Jan 1, 2017
-18.43 USD
Jan 1, 2018
-33.23 USD
Jan 1, 2019
-36.04 USD
Jan 1, 2020
-75.51 USD
Jan 1, 2021
-50.69 USD
Jan 1, 2022
-144.32 USD
Jan 1, 2023
-89.17 USD
The Notable Labs CROIC history
YEARCROICYoY
-89.17 %-38.21%
-144.32 %+184.71%
-50.69 %-32.87%
-75.51 %+109.48%
-36.04 %+8.46%
-33.23 %+80.37%
-18.43 %-43.79%
-32.78 %-13.64%
-37.96 %-3.17%
-39.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Cash Return on Invested Capital (CROIC) of Notable Labs is -89.17 % in 2023.

Cash Return on Invested Capital (CROIC) of Notable Labs changed from -144.32 % to -89.17 %, representing a -38.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Notable Labs with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Notable Labs

All Key Metrics — Notable Labs